FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to the use of an antibody or an immunoconjugate containing the antibody for treating non-squamous non-small cell lung cancer. Also disclosed is a method of treating non-squamous non-small cell lung cancer.
EFFECT: invention provides effective treatment of non-squamous non-small cell lung cancer.
30 cl, 4 dwg, 9 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| CONJUGATES OF ANTIBODY TO CCR7 AND DRUG | 2018 |
|
RU2777662C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| CD37-BINDING MOLECULES AND THEIR IMMUNOCONJUGATES | 2011 |
|
RU2742743C2 |
| HUMAN CYTOMEGALOVIRUS ANTIBODY AND USE THEREOF | 2020 |
|
RU2817217C1 |
| METHODS OF USING IMMUNOCONJUGATES CONTAINING ANTI-CD79B ANTIBODY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | 2020 |
|
RU2827797C1 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | 2016 |
|
RU2739612C2 |
| BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3 | 2020 |
|
RU2827106C1 |
| FULLY HUMAN MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN | 2016 |
|
RU2748281C2 |
